Strategic Blueprint’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Strategic Blueprint's VRTX Position: Q2 2026 in Review
Strategic Blueprint increased its Vertex Pharmaceuticals (VRTX) stake by 10% in Q2 2026, buying an estimated $32.8K and bringing the position to 795 shares worth $395K. The position accounts for 0.02% of the portfolio, ranked #510.
Strategic Blueprint first reported a position in VRTX in Q3 2020 and has held it in 13 quarters since. The position peaked at $804K in Q2 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Strategic Blueprint held 795 shares of Vertex Pharmaceuticals worth $395K as of Q2 2026.
- Strategic Blueprint bought 74 Vertex Pharmaceuticals shares in Q2 2026, an estimated $32.8K.
- Vertex Pharmaceuticals made up 0.02% of Strategic Blueprint's portfolio in Q2 2026, its #510 holding.
- Strategic Blueprint first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 13 quarters since.
- Strategic Blueprint's Vertex Pharmaceuticals position peaked at $804K in Q2 2025.
- 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Strategic Blueprint's 13F filing for Q2 2026, filed 23 Jul 2026.